Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on August 24, 2005
Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2005050463
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2005050463v1
16/10/3015    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chapman, J. R.
Right arrow Articles by Nankivell, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, J. R.
Right arrow Articles by Nankivell, B. J.

DISEASE OF THE MONTH

Chronic Renal Allograft Dysfunction

Jeremy R. Chapman 1*, Philip J. O’Connell 1, Brian J. Nankivell 1

1

Centre for Transplant and Renal Research, Department of Renal Medicine, Westmead Hospital, University of Sydney, Sydney, Australia


* To whom correspondence should be addressed. E-mail: jeremy_chapman{at}wsahs.nsw.gov.au.


  Abstract

The major causes of renal transplant loss are death from vascular, malignant or infectious disease, and loss of the allograft from chronic renal dysfunction associated with the development of graft fibrosis and glomerulosclerosis. Chronic allograft nephropathy (CAN) is the histologic description of the fibrosis, vascular and glomerular damage occurring in renal allografts. Clinical programs rely on monitoring change in serum creatinine for identification of patients at risk of CAN, but this change occurs late in the course of the disease, and underestimates the severity of pathologic change. CAN has several causes: ischemia-reperfusion injury, ineffectively or untreated clinical and subclinical rejection, and superimposed calcineurin inhibitor nephrotoxicity, exacerbating pre-existing donor disease. Once established, interstitial fibrosis and arteriolar hyalinosis lead to progressive glomerulosclerosis over the subsequent years. There have been a number of approaches to treatment aimed at reducing the impact of CAN, mostly centered around avoidance of calcineurin inhibitors through their elimination in all, or just selected, patients. These immunosuppression strategies combine corticosteroids with azathioprine or mycophenolate mofetil, and/or sirolimus and everolimus. Late identification of CAN in individual patients has meant that strategies for intervening to prevent chronic renal allograft dysfunction and subsequent graft loss tend to be "too little and far too late."


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
S. Chadban
New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients
Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1816 - 1818.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Seron, W. Arns, and J. R. Chapman
Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies
Nephrol. Dial. Transplant., April 2, 2008; (2008) gfn130v1.
[Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. S. Leong, B. M. Mahesh, J. R. Day, J. D. Smith, A. D. McCormack, G. Ghimire, T. J. Podor, and M. L. Rose
Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor
J. Leukoc. Biol., February 1, 2008; 83(2): 263 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Mahesh, H.-S. Leong, A. McCormack, P. Sarathchandra, A. Holder, and M. L. Rose
Autoantibodies to Vimentin Cause Accelerated Rejection of Cardiac Allografts
Am. J. Pathol., April 1, 2007; 170(4): 1415 - 1427.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
A. Grenz, T. Eckle, H. Zhang, D. Y. Huang, M. Wehrmann, C. Kohle, K. Unertl, H. Osswald, and H. K. Eltzschig
Use of a hanging-weight system for isolated renal artery occlusion during ischemic preconditioning in mice
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F475 - F485.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. C.-W. Tang, K. W. Chan, C. S.-O. Tang, M. F. Lam, C. Y. Leung, K. C. Tse, C. S. Li, Y. W. Ho, M. K.-L. Tong, K. N. Lai, et al.
Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy
Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3243 - 3251.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. R. Chapman and B. J. Nankivell
Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2060 - 2063.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. Harmon, K. Meyers, J. Ingelfinger, R. McDonald, M. McIntosh, M. Ho, L. Spaneas, J. A. Palmer, M. Hawk, C. Geehan, et al.
Safety and Efficacy of a Calcineurin Inhibitor Avoidance Regimen in Pediatric Renal Transplantation
J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1735 - 1745.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673